Acadian Asset Management LLC Tcr2 Therapeutics Inc. Transaction History

Acadian Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.0 - $1.62 $62,394 - $101,078	-62,394 Reduced 7.13%	812,459 $1.22 Million
Q4 2022 Feb 14, 2023	BUY	$0.83 - $1.44 $159,143 - $276,104	191,739 Added 28.07%	874,853 $872,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $262,704 - $529,646	141,239 Added 26.06%	683,114 $1.23 Million
Q2 2022 Aug 09, 2022	BUY	$2.11 - $2.94 $131,573 - $183,329	62,357 Added 13.0%	541,875 $1.57 Million
Q1 2022 May 12, 2022	BUY	$2.4 - $4.71 $1.12 Million - $2.19 Million	465,207 Added 3250.7%	479,518 $1.32 Million

Q4 2021 Feb 10, 2022	BUY	$4.58 - $8.34 $65,544 - $119,353	14,311 New	14,311 $65,000
Q2 2020 Aug 12, 2020	SELL	$6.51 - $16.85 $11,496 - $29,757	-1,766 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$6.01 - $16.01 $10,613 - $28,273	1,766 New	1,766 $14,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.